Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
|Articles|November 4, 2021
GenScript Opens New Gene Synthesis Center in New Jersey
Author(s)BioPharm International Editors
GenScript’s new gene synthesis center in Piscataway, NJ, is highly automated to accelerate production time and increase supply chain resiliency for biopharma and synthetic biology.
Advertisement
GenScript USA, a life science research tools and services provider, announced on Nov. 2, 2021 that it opened a new highly automated facility for gene synthesis and plasmid preparation services in Piscataway, NJ. The new larger-than-50,000-ft2 facility expands the company's advanced gene synthesis services and is designed to mitigate supply chain risks in the United States for new vaccines, therapeutics, and innovations in synthetic biology. The new facility is GenScript's first automated manufacturing site in the US and represents a 10-fold increase in capacity.
"GenScript is extremely committed to supporting our customers as they expand globally, and this specialized laboratory and manufacturing facility allows us to deliver reliable products to them faster than ever before," said Ray Chen, president of GenScript USA Life Science Group, in a company press release. "Importantly, this site also gives our US customers additional production resilience in case of unexpected events, such as pandemics and changes in customs and trade regulations."
"We are fortunate to be located in an area where this in an abundance of talent and expertise," Chen added. "With this facility, we also intend to add 100–200 jobs in research and manufacturing over the next two years."
Source: GenScript
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5